Mahendra Takashi Bhati, MD
Psychiatry · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 4
- 1 carrier
- Offices
- 2
Offices
2 locations · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
4 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Bhati’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence C141001 · Current
Licensed to practise in California · since 2016 · expires 2027-04-30 · Louisiana State University School of Medicine in Shreveport.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$38,716
Medicare paid this office $38,716 for 77 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Treatment using magnetic field to stimulate nerve cells in brain, subsequent delivery and management | 27 | $17,667 | $119 |
| Therapy using electrical currents | 32 | $8,964 | $91 |
| Long return visit (40+ min) | 18 | $5,491 | $162 |
| Treatment using magnetic field to stimulate nerve cells in brain, initial delivery and management | 12 | $2,706 | $208 |
Who their Medicare patients are
77 Original Medicare patients in 2024. Average age 69 · Women 65% · Also on Medicaid 23% · Health risk score 1.29. At or below the middle of the specialty; the typical psychiatry clinician is at 1.35.
Conditions among them: Depression 75% · High blood pressure 61% · Diabetes 30% · Dementia 19% · Chronic kidney disease 18% · Coronary heart disease 17% · Cancer 14%.
The office billed $527,794, Medicare allowed $49,510 and paid $38,716; for 330 services of 12 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 77 | 330 | 69 | 1.29 | $527,794 | $38,716 |
| 2023 | 54 | 372 | 71 | 1.54 | $321,281 | $37,516 |
| 2022 | 47 | 282 | 68 | 1.39 | $230,208 | $26,991 |
| 2021 | 57 | 432 | 68 | 1.56 | $365,072 | $43,306 |
| 2020 | 51 | 350 | 69 | 1.37 | $273,465 | $35,950 |
| 2019 | 61 | 431 | 71 | 1.20 | $302,000 | $37,013 |
| 2018 | 70 | 391 | 65 | 1.28 | $175,300 | $20,529 |
| 2017 | 60 | 368 | 66 | 1.33 | $128,796 | $19,737 |
| 2016 | 120 | 356 | 63 | 1.77 | $71,574 | $18,486 |
| 2015 | 185 | 760 | 60 | 1.43 | $99,701 | $39,498 |
| 2014 | 194 | 771 | 59 | 1.20 | $95,225 | $40,229 |
| 2013 | 183 | 683 | 59 | 1.19 | $87,658 | $28,883 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 4 services
| Therapy using electrical currents | 28 | $13,151 | $95 |
| Long return visit (40+ min) | 21 | $9,241 | $165 |
| Treatment using magnetic field to stimulate nerve cells in brain, subsequent delivery and management | 11 | $8,036 | $122 |
| Telehealth originating site facility fee | 26 | $1,484 | $22 |
2022: 2 services
| Therapy using electrical currents | 27 | $13,073 | $93 |
| Telehealth originating site facility fee | 18 | $915 | $22 |
2021: 4 services
| Therapy using electrical currents | 31 | $22,991 | $98 |
| Treatment using magnetic field to stimulate nerve cells in brain, subsequent delivery and management | 12 | $6,876 | $113 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 13 | $1,290 | $92 |
| Telehealth originating site facility fee | 17 | $995 | $22 |
2020: 2 services
| Treatment using magnetic field to stimulate nerve cells in brain, subsequent delivery and management | 19 | $16,075 | $118 |
| Therapy using electrical currents | 24 | $10,453 | $101 |
2019: 3 services
| Treatment using magnetic field to stimulate nerve cells in brain, subsequent delivery and management | 17 | $12,462 | $116 |
| Therapy using electrical currents | 24 | $12,168 | $99 |
| Treatment using magnetic field to stimulate nerve cells in brain, subsequent delivery and management | 19 | $1,825 | $22 |
2018: 5 services
| Therapy using electrical currents | 14 | $4,281 | $97 |
| Therapy using electrical currents | 16 | $3,869 | $86 |
| Treatment using magnetic field to stimulate nerve cells in brain, subsequent delivery and management | 25 | $3,738 | $22 |
| Psychotherapy with evaluation and management visit, 45 minutes | 12 | $2,676 | $64 |
| Short return visit (20+ min) | 13 | $779 | $37 |
2017: 5 services
| Psychotherapy with evaluation and management visit, 45 minutes | 13 | $3,252 | $65 |
| Treatment using magnetic field to stimulate nerve cells in brain, subsequent delivery and management | 25 | $3,230 | $22 |
| Therapy using electrical currents | 11 | $2,724 | $97 |
| New patient visit (60+ min) | 14 | $2,104 | $150 |
| Long return visit (40+ min) | 11 | $1,196 | $100 |
2016: 4 services
| Therapy using electrical currents | 23 | $4,839 | $91 |
| Psychotherapy with evaluation and management visit, 30 minutes | 29 | $2,730 | $44 |
| Short return visit (20+ min) | 56 | $2,593 | $32 |
| Short return visit | 29 | $1,026 | $19 |
2015: 7 services
| Short return visit (20+ min) | 123 | $11,272 | $38 |
| Therapy using electrical currents | 24 | $10,377 | $87 |
| Psychotherapy with evaluation and management visit, 30 minutes | 35 | $6,630 | $49 |
| Psychotherapy with evaluation and management visit, 45 minutes | 12 | $3,249 | $66 |
| Return visit (30+ min) | 26 | $2,676 | $61 |
| Psychiatric diagnostic evaluation with medical services | 25 | $2,387 | $95 |
| Short return visit | 28 | $1,358 | $20 |
2014: 7 services
| Short return visit (20+ min) | 109 | $10,236 | $39 |
| Psychotherapy with evaluation and management visit, 30 minutes | 35 | $8,298 | $51 |
| Therapy using electrical currents | 26 | $8,236 | $92 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 29 | $4,054 | $58 |
| Psychiatric diagnostic evaluation with medical services | 29 | $3,077 | $106 |
| Return visit (30+ min) | 33 | $2,909 | $58 |
| Short return visit | 28 | $1,515 | $19 |
2013: 7 services
| Short return visit (20+ min) | 119 | $10,295 | $31 |
| Therapy using electrical currents | 23 | $6,532 | $79 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 28 | $3,405 | $58 |
| Psychotherapy with evaluation and management visit, 30 minutes | 26 | $2,661 | $27 |
| Psychiatric diagnostic evaluation with medical services | 24 | $2,063 | $86 |
| Return visit (30+ min) | 15 | $922 | $49 |
| Short return visit | 15 | $348 | $17 |
Drugs they prescribed that Part D paid
$4,468
Pharmacies billed $4,468 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 98) in 2024. At or below the middle of the specialty; the typical psychiatry clinician is at 0%.
98 generic and 0 brand-name prescriptions · $4,468 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Bupropion Xl | 24 | $1,476 | $61 |
| Methylphenidate | 14 | $458 | $33 |
| Aripiprazole | 15 | $371 | $25 |
| Sertraline | 12 | $72 | $6 |
Year by year
| 2024 | 98 | None | 0% (0) | 0% | $4,468 |
| 2023 | 121 | None | 0% (0) | 0% | $6,137 |
| 2022 | 146 | None | 0% (0) | None | $11,496 |
| 2021 | 136 | None | 0% (0) | 0% | $8,761 |
| 2020 | 146 | None | 0% (0) | 10% | $18,520 |
| 2019 | 151 | 11 | None | 10% | $12,349 |
| 2018 | 145 | 15 | 0% (0) | None | $8,726 |
| 2017 | 127 | 19 | 0% (0) | None | $3,872 |
| 2016 | 410 | 55 | 0% (0) | 9% | $41,151 |
| 2015 | 749 | 71 | 0% (0) | None | $68,550 |
| 2014 | 851 | 83 | None | None | $80,451 |
| 2013 | 848 | 81 | 0% (0) | 13% | $71,340 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 3 drugs
| Aripiprazole | 16 | $1,956 | $122 |
| Bupropion Xl | 24 | $944 | $39 |
| Sertraline | 12 | $38 | $3 |
2022: 5 drugs
| Aripiprazole | 16 | $2,718 | $170 |
| Bupropion Xl | 27 | $2,473 | $92 |
| Gabapentin | 13 | $1,744 | $134 |
| Methylphenidate | 13 | $458 | $35 |
| Quetiapine | 13 | $236 | $18 |
2021: 5 drugs
| Bupropion Xl | 18 | $1,805 | $100 |
| Gabapentin | 17 | $1,225 | $72 |
| Methylphenidate | 15 | $577 | $38 |
| Trazodone | 11 | $518 | $47 |
| Fluvoxamine Maleate | 12 | $324 | $27 |
2020: 4 drugs
| Bupropion Xl | 12 | $1,703 | $142 |
| Quetiapine | 16 | $763 | $48 |
| Gabapentin | 13 | $635 | $49 |
| Methylphenidate | 15 | $283 | $19 |
2019: 5 drugs
| Viibryd | 11 | $3,234 | $294 |
| Bupropion Xl | 15 | $2,190 | $146 |
| Quetiapine | 17 | $373 | $22 |
| Methylphenidate | 17 | $339 | $20 |
| Venlafaxine Hcl Er | 16 | $331 | $21 |
2018: 6 drugs
| Bupropion Xl | 11 | $739 | $67 |
| Methylphenidate | 16 | $690 | $43 |
| Quetiapine | 11 | $512 | $47 |
| Venlafaxine Hcl Er | 24 | $425 | $18 |
| Zolpidem | 12 | $68 | $6 |
| Clonazepam | 11 | $61 | $6 |
2017: 4 drugs
| Quetiapine | 12 | $394 | $33 |
| Venlafaxine Hcl Er | 21 | $335 | $16 |
| Alprazolam | 11 | $229 | $21 |
| Topiramate | 12 | $182 | $15 |
2016: 11 drugs
| Bupropion Xl | 48 | $4,016 | $84 |
| Venlafaxine Hcl Er | 25 | $1,116 | $45 |
| Mirtazapine | 19 | $628 | $33 |
| Clonazepam | 69 | $429 | $6 |
| Topiramate | 14 | $321 | $23 |
| Quetiapine | 16 | $314 | $20 |
| Trazodone | 20 | $309 | $15 |
| Levothyroxine | 19 | $268 | $14 |
| Lamotrigine | 11 | $112 | $10 |
| Propranolol | 11 | $86 | $8 |
| Lithium Carbonate | 19 | $70 | $4 |
2015: 23 drugs
| Clomipramine | 11 | $11,088 | $1,008 |
| Bupropion Xl | 62 | $4,745 | $77 |
| Clozapine | 13 | $1,999 | $154 |
| Methylphenidate | 19 | $1,134 | $60 |
| Buspirone | 16 | $975 | $61 |
| Clonazepam | 127 | $821 | $6 |
| Fluoxetine | 27 | $751 | $28 |
| Escitalopram | 28 | $685 | $24 |
| Gabapentin | 26 | $654 | $25 |
| Venlafaxine Hcl Er | 18 | $530 | $29 |
| Mirtazapine | 32 | $454 | $14 |
| Trazodone | 44 | $387 | $9 |
| Quetiapine | 23 | $364 | $16 |
| Nortriptyline | 17 | $345 | $20 |
| Levothyroxine | 19 | $332 | $17 |
| Topiramate | 15 | $321 | $21 |
| Lamotrigine | 30 | $296 | $10 |
| Sertraline | 13 | $249 | $19 |
| Lithium Carbonate | 23 | $170 | $7 |
| Paroxetine | 11 | $152 | $14 |
| Alprazolam | 14 | $133 | $10 |
| Risperidone | 14 | $129 | $9 |
| Lorazepam | 11 | $112 | $10 |
2014: 24 drugs
| Clomipramine | 14 | $12,220 | $873 |
| Modafinil | 13 | $7,151 | $550 |
| Bupropion Xl | 53 | $4,390 | $83 |
| Duloxetine | 13 | $4,123 | $317 |
| Paroxetine | 16 | $2,095 | $131 |
| Venlafaxine Hcl Er | 26 | $2,066 | $79 |
| Methylphenidate | 37 | $1,494 | $40 |
| Fluoxetine | 36 | $1,446 | $40 |
| Gabapentin | 41 | $1,416 | $35 |
| Clonazepam | 162 | $1,087 | $7 |
| Buspirone | 12 | $1,058 | $88 |
| Quetiapine | 28 | $1,050 | $37 |
| Mirtazapine | 27 | $497 | $18 |
| Trazodone | 34 | $388 | $11 |
| Lamotrigine | 24 | $375 | $16 |
| Sertraline | 25 | $329 | $13 |
| Nortriptyline | 19 | $322 | $17 |
| Levothyroxine | 12 | $179 | $15 |
| Lorazepam | 17 | $177 | $10 |
| Doxepin | 12 | $157 | $13 |
| Lithium Carbonate | 12 | $148 | $12 |
| Risperidone | 17 | $140 | $8 |
| Escitalopram | 11 | $119 | $11 |
| Alprazolam | 11 | $48 | $4 |
2013: 26 drugs
| Modafinil | 22 | $14,695 | $668 |
| Abilify | 12 | $9,509 | $792 |
| Bupropion Xl | 47 | $3,836 | $82 |
| Dextroamphetamine-Amphetamine | 11 | $2,717 | $247 |
| Clomipramine | 11 | $2,655 | $241 |
| Paroxetine | 15 | $2,091 | $139 |
| Venlafaxine Hcl Er | 30 | $2,041 | $68 |
| Quetiapine | 39 | $1,927 | $49 |
| Desipramine | 13 | $1,518 | $117 |
| Buspirone | 13 | $1,342 | $103 |
| Gabapentin | 39 | $1,272 | $33 |
| Pramipexole Dihydrochloride | 13 | $1,023 | $79 |
| Clonazepam | 162 | $986 | $6 |
| Fluoxetine | 24 | $713 | $30 |
| Methylphenidate | 27 | $708 | $26 |
| Trifluoperazine | 11 | $568 | $52 |
| Alprazolam Er | 17 | $558 | $33 |
| Risperidone | 28 | $500 | $18 |
| Escitalopram | 11 | $443 | $40 |
| Alprazolam | 21 | $335 | $16 |
| Lamotrigine | 27 | $332 | $12 |
| Sertraline | 19 | $270 | $14 |
| Trazodone | 24 | $188 | $8 |
| Zolpidem | 25 | $164 | $7 |
| Levothyroxine | 15 | $141 | $9 |
| Lorazepam | 13 | $86 | $7 |
Money from drug and device companies
$92 in 2024
| 2024 | 1 | 1 | None | $92 |
| 2023 | 1 | 10 | None | $1,326 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| LivaNova USA | Vns Therapy Symmetry Model 8103 Generator | $92 | 1 payment
|
See the published payment
| LivaNova USA | Meals · 2024-05-14 | Vns Therapy Symmetry Model 8103 Generator | $92 |
See earlier years (2023)
2023: $1,326
| Abbott Laboratories | Infinity | $1,326 | 10 payments
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Medtronic USA, Inc. · Reclaim · 2019 | Their institution | $2,370 |
| Medtronic, Inc. · Reclaim · 2021 | Their institution | $474 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1013052513
- Licence
- CA C141001, PA MD422908California C141001: Current · expires 2027-04-30
- Trained
- Louisiana State University School of Medicine in New Orleans, 2001
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Psychiatry (2084P0800X)
- Mailing address
- 300 Pasteur Dr, Palo Alto, CA, 94304
- NPI first listed
- 2007-02-21
- NPI last updated
- 2024-04-29
- NPI record certified
- 2024-04-29
This is when the NPI record was last certified, not a medical board exam.